The "collateral damage" of the war on COVID-19: impact of the pandemic on the care of epithelial ovarian cancer.
Luxitaa Goenka, Annuja Anandaradje, Tejaeswar Nakka...
https://pubmed.ncbi.nlm.nih.gov/34581889/Actively Recruiting
Led by Azienda USL Reggio Emilia - IRCCS · Updated on 2026-07-24
200
Participants Needed
7
Research Sites
52 weeks
Total Duration
This observational study investigates the impact of surgical centralization and treatment strategies on oncologic outcomes in female patients diagnosed with epithelial ovarian cancer EOC between 2018 and 2023 within the Emilia-Romagna region in Italy. The study aims to compare progression-free survival and overall survival across three time periods before centralization and the COVID-19 pandemic, during the pandemic peak, and during the post-pandemic control phase. This research is conducted by the AUSL-IRCCS of Reggio Emilia and includes both retrospective and prospective components. Participants are grouped based on when they received treatment prior to centralization and the pandemic 2018-2019, during the peak pandemic with changes in care due to resource limitations 2020-2021, and after the pandemic peak reflecting new care standards 2022-2023. No experimental treatments are given, as all patients receive standard care according to routine clinical practice. The study observes variations in surgical approaches, chemotherapy, and use of therapies like Bevacizumab and PARP inhibitors. Throughout the study, participants clinical records and outcomes are reviewed retrospectively, with ongoing clinical follow-up planned for up to five years. Researchers assess survival rates, treatment types, tumor characteristics, recurrence patterns, and use of secondary treatments including surgery and radiotherapy. Data collection includes information from multidisciplinary tumor boards and patient consents. The study spans until June 2031, allowing comprehensive evaluation of long-term outcomes.
CONDITIONS
Centralization and Oncologic Outcomes in Ovarian Cancer
V
Vincenzo Dario Mandato, MD - Principal Investigator
J
Jasmine Lonetti
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda USL Reggio Emilia - IRCCS
Lead Sponsor
AUSL di Modena - Ospedale Ramazzini di Carpi
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years from diagnosis
Participants' medical records are reviewed, and their health outcomes are monitored over time according to routine clinical practice. Follow-up includes tracking treatment details, tumor characteristics, and survival outcomes.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Luxitaa Goenka, Annuja Anandaradje, Tejaeswar Nakka...
https://pubmed.ncbi.nlm.nih.gov/34581889/Vincenzo Dario Mandato, Lorenzo Aguzzoli
https://pubmed.ncbi.nlm.nih.gov/32275775/Vincenzo Dario Mandato, Federica Torricelli, Stefano Uccella...
https://pubmed.ncbi.nlm.nih.gov/34149908/Delphine Hudry, Stéphanie Bécourt, Giovanni Scambia...
https://pubmed.ncbi.nlm.nih.gov/35969358/Christina Fotopoulou, Nicole Concin, François Planchamp...
https://pubmed.ncbi.nlm.nih.gov/32086362/Hyuna Sung, Jacques Ferlay, Rebecca L Siegel...
https://pubmed.ncbi.nlm.nih.gov/33538338/Vincenzo Dario Mandato, Martino Abrate, Pierandrea De Iaco...
https://pubmed.ncbi.nlm.nih.gov/23547941/N Colombo, C Sessa, A du Bois...
https://pubmed.ncbi.nlm.nih.gov/31048403/Dennis S Chi, Fernanda Musa, Fanny Dao...
https://pubmed.ncbi.nlm.nih.gov/21917306/Vincenzo Dario Mandato, Federica Torricelli, Valentina Mastrofilippo...
https://pubmed.ncbi.nlm.nih.gov/37358270/Azienda USL Reggio Emilia - IRCCS
Lead Sponsor
AUSL di Modena - Ospedale Ramazzini di Carpi
Collaborating Sponsor